# US 2011/0236999 A1 · Hydrogel Nanoparticle Based Immunoassay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0236999 A1
- Document ID: US20110236999A1
- Status: Published application
- Kind: A1
- Application number: 13/061,507
- Filed: 2009-08-26
- Published: 2011-09-29
- Earliest claimed: 2008-08-26
- Assignees: George Mason Research Foundation, Inc.
- Inventors: Lance A. Liotta; Alessandra Luchini; Emaneul F. Petricoin; Virginia Espina
- Web page: https://patentgrep.com/patent/US20110236999A1

## CPC

- G01N 33/521: {Single-layer analytical elements}
- G01N 33/54333: {Modification of conditions of immunological binding reaction, e.g. use of more than one type of particle, use of chemical agents to improve binding, choice of incubation time or application of magnetic field during binding reaction}
- G01N 33/54346: {Nanoparticles}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An immunoassay device incorporating porous polymeric capture nanoparticles within either the sample collection vessel or pre-impregnated into a porous substratum within fluid flow path of the analytical device is presented. This incorporation of capture particles within the immunoassay device improves sensitivity while removing the requirement for pre-processing of samples prior to loading the immunoassay device. A preferred embodiment is coreshell bait containing capture nanoparticles which perform three functions in one step, in solution: a) molecular size sieving, b) target analyte sequestration and concentration, and c) protection from degradation. The polymeric matrix of the capture particles may be made of co-polymeric materials having a structural monomer and an affinity monomer, the affinity monomer having properties that attract the analyte to the capture particle. This device is useful for point of care diagnostic assays for biomedical applications and as field deployable assays for environmental, pathogen and chemical or biological threat identification.

## Claims

### Claim 1

An immunoassay system, comprising:
incorporating analyte enrichment and an isolation step into a lateral flow immunoassay device such that the analyte enrichment and the isolation step are conducted by particles ranging in size from 1 nm to 100 μm;
containing an affinity bait internally within the particles;
exposing a sample fluid containing analyte to a zone of nanoparticles, the nanoparticles comprising an open polymeric meshwork that encloses the affinity bait;
recognizing the analyte via the affinity bait and the open polymeric meshwork;
preventing degradation of the analyte inside the particles by concentrating and sequestering the analyte;
releasing the analyte such that the analyte is recognized by a ligand that is labeled; and
releasing the analyte such that the analyte is recognized by an antibody that is labeled.

### Claim 2 (depends on 1)

The system of claim 1, further comprising suspending the particles in the sample fluid containing the analyte such that the particles that are suspended are of such buoyancy that the particles will remain in the sample fluid without settling.

### Claim 3 (depends on 2)

The system of claim 2, further comprising maintaining the particles that are suspended such that the particles are of an open polymeric structure that is greater than 80 percent occupied by the sample fluid.

### Claim 4 (depends on 1)

The system of claim 1, further comprising applying a mixture of the particles and the sample fluid to the lateral flow immunoassay device such that the particles are deposited and immobilized into the zone of nanoparticles, the zone of nanoparticles being within lateral flow immunoassay device and within a path of the sample fluid.

### Claim 5 (depends on 1)

The system of claim 1, further comprising capturing the particles via the device, the particles comprising of a polymetric matrix shell, the polymetric matrix shell having a pore size that allows for the analyte to enter the polymetric matrix shell while preventing other compounds located within the sample fluid to enter the polymetric matrix shell, and an internal core containing an immobilized affinity ligand, the affinity ligand formed to recognize the analyte.

### Claim 6 (depends on 5)

The system of claim 5, further comprising incorporating the particles that are captured into a porous substratum as part of the lateral flow immunoassay device.

### Claim 7 (depends on 5)

The system of claim 5, further comprising altering a flow path of the sample fluid after the particles have sequestered the analyte.

### Claim 8 (depends on 5)

The system of claim 5, further comprising causing the particles that are captured to flow within the zone of nanoparticles by wicking through different porosities when the particles are in a size range from 1 nanometer to 1000 nanometers.

### Claim 9 (depends on 1)

The system of claim 1, further comprising including the sample fluid that is derived from a biological source.

### Claim 10 (depends on 1)

The system of claim 1, further comprising including the sample fluid that is derived from a non-biological source.

### Claim 11 (depends on 1)

The system of claim 1, further comprising separating target biomarkers from the particles that are captured such that an extraction buffer is utilized to remove the biomarkers that are sequestered from the particles that are captured.

### Claim 12 (depends on 1)

The system of claim 1, further comprising sequestering, concentrating and protecting proteins, peptides and nucleic acid biomarkers from degradation by contacting the sample fluid with the particles that are captured, the particles being a polymeric matrix having a pore size that allows for the analyte to enter the polymetric matrix while preventing other compounds located within the sample fluid to enter the polymetric matrix.

### Claim 13 (depends on 1)

The system of claim 1, further comprising incorporating a population of the particles that are captured with the lateral flow immunoassay device when the particles contain multiple subpopulations specific for individual classes of low molecular weight molecules present in the sample fluid.

### Claim 14 (depends on 1)

The system of claim 1, further comprising pre-concentrating and preserving the analyte when the analyte is present in the sample fluid and in the presence of hydrogel particles that contain the affinity bait for the analyte such that the hydrogel particles are of sufficient size and buoyancy to remain in the sample fluid, as well as when a high proportion of the analyte is sequestered within the hydrogel particles and a bulk of spent sample fluid volume is wicked away within a porous matrix.

### Claim 15 (depends on 1)

The system of claim 1, further comprising trapping the analyte within a capture particle, the capture particle formed by a molecular sieve portion and an analyte binding portion such that the molecular sieve portion and the analyte binding portion have a cross-linked region of a modified porosity while the molecular sieve portion is configured to contract and expand in response to physical and chemical treatment in order to trap the analyte within the capture particle.

### Claim 16 (depends on 15)

The system of claim 15, further comprising forming the analyte binding portion to be at least one type of moiety that is capable of chemically and electrostatically binding and sequestering the analyte.

### Claim 17 (depends on 15)

The system of claim 15, further comprising forming the analyte binding portion to include a combination of a carboxy group, amine group, lipid, phosphoprotein, phospholipids, amide group, hydroxyl group, ester group, acrylic group, thiol group, acrylic acid, antibodies, binding proteins, binding pairs, metals, chelating agents, nucleic acids, aptamers, enzyme-binding pockets, lectins, pharmacologic agent, synthetic peptides, antibody fragments, hydrophobic surface, and a hydrophilic surface.

### Claim 18 (depends on 15)

The system of claim 15, further comprising binding the analyte to the analyte binding portion such that the analyte is a combination of organic molecules, inorganic molecules, polypeptides, carbohydrates, nucleic acids, and lipids.

### Claim 19 (depends on 15)

The system of claim 15, further comprising forming the molecular sieve portion to be an outer shell enclosing an inner core, the inner core made up of the analyte binding portion.

### Claim 20

An immunoassay system, comprising:
incorporating analyte enrichment and an isolation step into a lateral flow immunoassay device such that the analyte enrichment and the isolation step are conducted by particles ranging in size from 1 nm to 100 μm;
containing an affinity bait internally within the particles;
exposing a sample fluid containing analyte to a zone of nanoparticles, the nanoparticles comprising an open polymeric meshwork that encloses the affinity bait;
recognizing the analyte via the affinity bait and the open polymeric meshwork;
preventing degradation of the analyte inside the particles by concentrating and sequestering the analyte;
releasing the analyte such that the analyte is recognized by a ligand that is labeled;
releasing the analyte such that the analyte is recognized by an antibody that is labeled;
further comprising suspending the particles in the sample fluid containing the analyte such that the particles that are suspended are of such buoyancy that the particles will remain in the sample fluid without settling;
further comprising maintaining the particles that are suspended such that the particles are of an open polymeric structure that is greater than 80 percent occupied by the sample fluid;
further comprising applying a mixture of the particles and the sample fluid to the lateral flow immunoassay device such that the particles are deposited and immobilized into the zone of nanoparticles, the zone of nanoparticles being within lateral flow immunoassay device and within a path of the sample fluid;
further comprising capturing the particles via the device, the particles comprising of a polymetric matrix shell, the polymetric matrix shell having a pore size that allows for the analyte to enter the polymetric matrix shell while preventing other compounds located within the sample fluid to enter the polymetric matrix shell, and an internal core containing an immobilized affinity ligand, the affinity ligand formed to recognize the analyte;
further comprising incorporating the particles that are captured into a porous substratum as part of the lateral flow immunoassay device;
further comprising altering a flow path of the sample fluid after the particles have sequestered the analyte;
further comprising causing the particles that are captured to flow within the zone of nanoparticles by wicking through different porosities when the particles are in a size range from 1 nanometer to 1000 nanometers;
further comprising including the sample fluid that is derived from a biological source;
further comprising including the sample fluid that is derived from a non-biological source;
further comprising separating target biomarkers from the particles that are captured such that an extraction buffer is utilized to remove the biomarkers that are sequestered from the particles that are captured;
further comprising sequestering, concentrating and protecting proteins, peptides and nucleic acid biomarkers from degradation by contacting the sample fluid with the particles that are captured, the particles being a polymeric matrix having a pore size that allows for the analyte to enter the polymetric matrix while preventing other compounds located within the sample fluid to enter the polymetric matrix;
further comprising incorporating a population of the particles that are captured with the lateral flow immunoassay device when the particles contain multiple subpopulations specific for individual classes of low molecular weight molecules present in the sample fluid;
further comprising pre-concentrating and preserving the analyte when the analyte is present in the sample fluid and in the presence of hydrogel particles that contain the affinity bait for the analyte such that the hydrogel particles are of sufficient size and buoyancy to remain in the sample fluid, as well as when a high proportion of the analyte is sequestered within the hydrogel particles and a bulk of spent sample fluid volume is wicked away within a porous matrix;
further comprising trapping the analyte within a capture particle, the capture particle formed by a molecular sieve portion and an analyte binding portion such that the molecular sieve portion and the analyte binding portion have a cross-linked region of a modified porosity while the molecular sieve portion is configured to contract and expand in response to physical and chemical treatment in order to trap the analyte within the capture particle;
further comprising forming the analyte binding portion to be at least one type of moiety that is capable of chemically and electrostatically binding and sequestering the analyte;
further comprising forming the analyte binding portion to include a combination of a carboxy group, amine group, lipid, phosphoprotein, phospholipids, amide group, hydroxyl group, ester group, acrylic group, thiol group, acrylic acid, antibodies, binding proteins, binding pairs, metals, chelating agents, nucleic acids, aptamers, enzyme-binding pockets, lectins, pharmacologic agent, synthetic peptides, antibody fragments, hydrophobic surface, and a hydrophilic surface;
further comprising binding the analyte to the analyte binding portion such that the analyte is a combination of organic molecules, inorganic molecules, polypeptides, carbohydrates, nucleic acids, and lipids;
further comprising forming the molecular sieve portion to be an outer shell enclosing an inner core, the inner core made up of the analyte binding portion;
further comprising forming the capture particle such that the molecular sieve portion and the analyte binding portion are comprised of a combination of polyacrylamide, poly(N-isopropylacrylamide), N-alkyl substituted polyacrylamide, poly(N-vinylalkylamide), poly(methacrylic acid), poly(benzyl glutamate), poly(2-ethylacrylic acid), poly(4-vinylpyridine);
further comprising forming a cross-linked region into the capture particle that is comprised of a combination of N,N′-methylenebisacrylamide, ethylene glycol dimethacrylate, tetraethylene glycol dimethacrylate, poly(ethyleneglycol)dimethacrylate;
further comprising including hydrogel into the molecular sieve portion and the analyte binder portion; and
further comprising releasing a sequestered analyte from the capture particle when exposed to a treatment exposure.
